According to Tonix Pharmaceuticals, researchers at Erasmus University Medical Center have initiated a Phase 1 study of Tonix’s TNX-1900 intranasal potentiated oxytocin in healthy female volunteers as a proof of concept for the potential use of the nasal spray for the treatment of migraine. The company reports that the trial will “evaluate the effect of TNX-1900 . . . on trigeminal nerve-mediated vasodilation of the forehead using capsaicin as well as electrical stimulation, a model for trigeminal neurovascular reactivity.” Tonix says that the study is taking place under a collaborative research agreement between the university and the company.
Tonix licensed TNX-1900 for the treatment of migraine from Trigemina in June 2020, and in 2023, the company announced the initiation of the Phase 2 PREVENTION study of TNX-1900 for the prevention of migraines. Tonix also licensed intranasal potentiated oxytocin for the treatment of insulin resistance from the University of Geneva in 2020, and in October 2025, the company announced the initiation of a Phase 1 trial by Massachusetts General Hospital to evaluate TNX-1900 and TNX-2900 oxytocin nasal sprays in patients with central diabetes insipidus. TNX-2900 is also in Phase 2 development for the treatment of Prader-Willi syndrome.
Tonix CEO Seth Lederman commented, “We are excited to collaborate with Professor Maassen van den Brink on this proof-of-concept study investigating the potential for TNX-1900 for treating migraine, craniofacial pain, and other related conditions. While there are several CGRP inhibitors approved for the treatment of migraine, TNX-1900’s oxytocin treatment affects a distinct pathway that could address unmet needs. The results of the new study will guide future development of this potential non-opioid treatment for migraine and other craniofacial pain conditions.”
Read the Tonix Pharmaceuticals press release
